Healthcare and biotech remain among the most capital-intensive and specialized corners of venture capital. Unlike generalist technology investing, backing a therapeutics or diagnostics company requires deep scientific diligence, patience through long development timelines, and fluency in regulatory and reimbursement pathways. The firms that have built credibility in this space tend to be run by scientists, physicians, and former operators as much as financiers. Here are nine US-based firms that remain active and influential in healthcare and biotech venture investing in 2025.
ARCH Venture Partners
Location: Chicago, IL and San Francisco, CA Focus: Biotechnology and life sciences company creation Stage: Seed through growth Founded in 1986 by Steven Lazarus, Keith Crandell, Robert Nelsen, and Clinton Bybee, ARCH Venture Partners is a premier firm headquartered in Chicago that specializes in backing disruptive science. ARCH distinguishes itself as a "bold and imaginative risk-taker," often investing in revolutionary technologies long before they are validated by the broader market. The firm is known for its deep roots in academia and national laboratories, originally spinning out of the University of Chicago’s technology transfer office. ARCH partners are famous for their hands-on approach to company creation, often originating ventures from whole cloth and supporting them with hundreds of millions of dollars in capital over their lifecycle. Their investment strategy is contrarian and long-term, focusing on areas like infectious disease, mental health, and oncology. Notable portfolio companies include Illumina, the global leader in DNA sequencing where ARCH was an early, critical backer; Moderna, where the firm was a key early-stage participant in its mRNA-focused journey; and Juno Therapeutics, a pioneer in CAR-T cell therapy that was acquired by Celgene for $9 billion. Other successful exits include Agios Pharmaceuticals and Denali Therapeutics. ARCH continues to be a high-conviction partner for scientific founders building at the technical frontier.
OrbiMed
Location: New York City, NY Focus: Biopharmaceuticals, medical devices, diagnostics, and healthcare IT Stage: Seed through public market investing OrbiMed was founded in 1989 (originally as Mehta & Isaly) by Samuel Isaly and Viren Mehta, and is now headquartered in New York City. The firm is one of the world's largest dedicated healthcare investment firms, managing approximately $21 billion in assets. OrbiMed distinguishes itself with a broad and flexible investment strategy that spans the entire healthcare industry, from seed-stage venture capital and private credit to public equity. Their team includes over 150 distinguished scientific, medical, and investment professionals, providing a level of domain expertise that is rare in generalist venture firms. OrbiMed typically acts as a lead investor, helping to build portfolio companies into market leaders across North America, Europe, and Asia. Notable portfolio companies include Argenx, a leader in immunology where OrbiMed was an early backer through its multi-billion dollar public success; Guardant Health, a pioneer in liquid biopsy for cancer detection; and Natera, a leader in cell-free DNA testing. They also provided critical financing for Intra-Cellular Therapies and Treeline Biosciences. OrbiMed is known for its ability to provide tailored financing solutions, including royalty monetization and structured debt, to support companies from discovery through commercialization.
Flagship Pioneering
Location: Cambridge, MA Focus: Company creation across human health and sustainability Stage: Pre-seed through growth Founded in 1999 by Noubar Afeyan and Ed Kania (originally as NewcoGen), Flagship Pioneering is a Cambridge-based firm that operates more as an "innovation engine" than a traditional venture firm. Flagship distinguishes itself through its systematic process of "Pioneering," where it originates companies inside its own labs (Flagship Labs) by asking "What if?" questions that explore unproven scientific spaces. The firm acts as the principal founder, funder, and owner of its companies, originating 8 to 10 "ProtoCos" each year. This unique model allows Flagship to maintain deep control over the scientific direction and executive leadership of its ventures. Noubar Afeyan, a serial entrepreneur and PhD engineer, has built a culture that emphasizes DREAMing big and LEAPing boldly. Notable portfolio companies include Moderna, which Flagship founded in 2010 to commercialize mRNA technology, leading to one of the most significant IPOs in biotech history; Foghorn Therapeutics, which focuses on chromatin remodeling; and Indigo Agriculture, a leader in sustainable farming technology. Other successful creations include Denali Therapeutics and Rubius Therapeutics. With over 120 companies founded since its inception, Flagship remains the most prolific company creator in the life sciences sector.
Third Rock Ventures
Location: Boston, MA and San Francisco, CA Focus: Biotechnology company formation Stage: Seed through growth Third Rock Ventures was established in 2007 by industry veterans Mark Levin, Kevin Starr, and Robert Tepper, with headquarters in Boston. The firm distinguishes itself through its "differentiated company-building process" that operates at the intersection of science, medicine, and business. Third Rock partners closely with leading academic scientists to build companies from scratch, often spending years in the "Discovery" phase to mature a lead program before a formal launch. Every team member brings decades of real-world operating experience from leading biotech and pharma companies, which they use to guide the strategy and culture of their ventures. The firm is known for its unwavering focus on "product engines"—technologies capable of generating multiple products across different disease areas. Notable portfolio companies include Sage Therapeutics, which the firm supported from its early days through the approval of the first drug for postpartum depression; Editas Medicine, a leader in CRISPR gene editing; and Bluebird Bio, a pioneer in gene therapy. Other successful investments include Constellation Pharmaceuticals and Flare Therapeutics. Third Rock has launched more than 70 companies to date, resulting in over 27 approved products that have reached millions of patients globally.
Polaris Partners
Location: Boston, MA Focus: Life sciences and technology Stage: Seed through growth Founded in 1996 by Jon Flint, Terry McGuire, and Steve Arnold, Polaris Partners is a Boston-headquartered firm with nearly three decades of experience backing transformational companies. The firm distinguishes itself by its deep-rooted history in both healthcare and technology, allowing it to bridge the gap between biological breakthroughs and digital innovation. Polaris partners are known as "builders" who leverage a vast network of prestigious universities and research institutions to source early-stage innovation. They manage over $5 billion in committed capital and are active across multiple specialized vehicles, including the Polaris Innovation Fund, which focuses on academic research. The firm is recognized for its long-term commitment to founders, with a track record of supporting over 400 companies and 50 IPOs. Notable life sciences portfolio companies include Alnylam Pharmaceuticals, a pioneer in RNA interference (RNAi) therapy where Polaris was a key early backer; Acceleron Pharma, which was acquired by Merck for $11.5 billion; and Freenome, a leader in early cancer detection through multiomics. They also backed Adimab and Seismic Therapeutic. Polaris continues to be a preferred partner for both first-time and repeat entrepreneurs building the future of medicine.
Versant Ventures
Location: San Francisco, CA Focus: Therapeutics and biotechnology company creation Stage: Seed through growth Versant Ventures was founded in 1999 by partners from Brentwood Associates, IVP, and Crosspoint Ventures, and is headquartered in San Francisco. The firm distinguishes itself as a global, science-focused investor with a robust "Discovery Engine" infrastructure. Versant operates several in-house lab facilities, including Inception Therapeutics in San Diego and Ridgeline in Basel, Switzerland, where multidisciplinary teams of scientists work to launch new companies with academic founders. This wet-lab capacity allows Versant to advance companies in stealth mode for years before they raise external capital. The firm manages approximately $5.5 billion and focuses on high-impact therapeutics across oncology, immunology, and metabolic diseases. Notable portfolio companies include Repare Therapeutics, a leader in synthetic lethality that was incubated inside Versant's engines; Monte Rosa Therapeutics, which specializes in protein degradation; and Crispr Therapeutics, which the firm supported in its early stages. Other successful exits include Quanticel Pharmaceuticals (acquired by Celgene) and Loxo Oncology (acquired by Eli Lilly for $8 billion). Versant remains a leader in transatlantic company building, with a strong presence in the U.S., Canada, and Europe.
Sofinnova Investments
Location: Menlo Park, CA Focus: Therapeutics and global biopharmaceuticals Stage: Late preclinical through public equity Sofinnova Investments (formerly Sofinnova Ventures) traces its origins to 1972 in France, with the U.S. firm established in 1976 by Jean Deléage. Headquartered in Menlo Park, the firm manages approximately $4.6 billion in assets and focuses exclusively on therapeutic drug development. Sofinnova distinguishes itself by its "full-lifecycle" approach to therapeutics, investing in both private companies at the late preclinical stage and publicly traded biotechs through its Sofinnova BioEquities strategy. The firm's team brings together scientific, clinical, and regulatory expertise to help entrepreneurs navigate the "valley of death" between discovery and commercialization. They are known for being collaborative board members who provide deep industry knowledge and strategic guidance. Notable portfolio companies include Genentech, where Jean Deléage was a legendary early investor in 1977; Atea Pharmaceuticals, which focuses on antiviral treatments; and Marea Therapeutics, a clinical-stage leader in cardioendocrine medicines. Other key holdings include Axonis Therapeutics and ARTBIO. The firm has a long legacy of building category-defining companies in both the U.S. and Europe, consistently focusing on products that aspire to meaningfully impact patient lives.
5AM Ventures
Location: San Francisco, CA and Menlo Park, CA Focus: Biopharmaceuticals, drug delivery, and life science tools Stage: Seed through Series A Founded in 2002 by Andrew Schwab and Dr. John Diekman, 5AM Ventures is a San Francisco-based firm that specializes in seed and early-stage life science investments. The firm distinguishes itself with its unusually hands-on "4:59 Initiative," an internal incubator that seeks to partner with academics to establish proof-of-concept data before a formal Series A financing. 5AM partners often assume short-term operating roles inside their portfolio companies, providing guidance on strategy, management hiring, and regulatory filings. The firm manages over $2 billion in capital and focuses on companies with validated development-stage assets and innovative platform technologies. Their professionals draw on over a century of combined operational experience as CEOs and leaders in the biotech industry. Notable portfolio companies include Achaogen, an anti-infective leader where 5AM was an early investor through its IPO; Akouos, a gene therapy pioneer for hearing loss that was acquired by Eli Lilly for $610 million; and Arvinas, a leader in targeted protein degradation. Other key investments include Homology Medicines and Precision NanoSystems. 5AM continues to be a top choice for founders looking for a highly engaged, "entrepreneur-friendly" lead investor.
RA Capital Management
Location: Boston, MA Focus: Healthcare, life sciences, and planetary health Stage: Seed through public markets RA Capital Management was founded in 2002 by Richard Aldrich (a co-founder of Vertex Pharmaceuticals) and Peter Kolchinsky. Headquartered in Boston, the firm manages over $14 billion in assets. RA Capital distinguishes itself by its "evidence-based" investment approach, powered by its proprietary TechAtlas research division. TechAtlas employs a large team of MDs and PhDs to map hundreds of disease and technology landscapes, providing a data-driven foundation for every investment decision. The firm is a "crossover" investor, meaning it has the flexibility to back companies at any stage, from NewCo origination and seed rounds through crossover financing and public market trading. RA Capital is known for its "upstream" investing, often providing enough capital for companies to pursue multiple programs in parallel rather than betting on a single binary event. Notable portfolio companies include Triangle Pharmaceuticals, an early win acquired by Gilead for $464 million; Ascendis Pharma, a global leader in hormone replacement therapies; and Argenx, which the firm supported through its multi-billion dollar expansion. They have financed over 70 approved drugs since inception and remain one of the most active lead investors in the biotech sector.
Healthcare fundraising requires more than just a good pitch; it requires a data room built for intense scientific scrutiny. Investors in this category will expect to see a clear path to clinical proof-of-concept and a sophisticated understanding of the competitive landscape. See our due diligence for healthcare startups for a checklist of the clinical and regulatory documentation you'll need.
If you're building a biotech or healthcare company and looking for a partner to help you navigate the path from the lab to the clinic, book a free consult with Quantum Growth Advisors. We work with founders across the life sciences to refine their strategy and connect with the right specialist capital.